Sign in
Taking people in ItalyPhase 2

Bumetanide for thinking skills in children and teens with Down syndrome

Tests bumetanide for thinking abilities in children and teens with Down syndrome.

Key facts

Who runs it
Ospedale Pediatrico Bambino Gesu
Where
Rome, ItalySee the site
Registry title
Assessing the efficacy of Bumetanide for the improvement of cognitive functions in children and adolescents with Down syndrome
Status
Recruiting
Phase
Phase 2
People taking part
64 people, planned
Started
11 Jan 2023
Expected to end
31 Dec 2026
Type of study
Interventional
Record updated
9 January 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children and teenagers with Down syndrome to test whether Bumetanide improves thinking skills, compared with placebo.

Age
10 to 17 years old (included).
Sex
All sexes can join.
Disease stage
Down syndrome with free trisomy 21 shown by a chromosome test (karyotyping). Mental age between 4.5 and 8.5, measured with the Leiter-3 test.
Earlier treatment
People already treated with diuretics (water pills) cannot join.
Biomarker or test result
Free trisomy 21 documented by karyotyping.

Main reasons for not taking part

  • Hearing loss, serious vision problems or epilepsy
  • Serious heart defects that needed or await surgery, or need heart medicines
  • Allergy to sulpha drugs, or other reasons Bumetanide cannot be used
  • Abnormal blood, liver or kidney test results, or QTc >450 msec on ECG
  • Weight less than 25 Kg (55 lb), or pregnancy

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • The presence of a free trisomy 21 documented by karyotyping 2) Adolescents from 10 to 17 years old (included) 3) 4.5 ≥ Mental age ≤ 8.5 (as assessed by Leiter-3 at visit 1 or by assessment with Leiter-3 within 6 months of the first visit (Visit 1) 4) Informed consent from each child and their parents

Who cannot take part

  • The presence of any neurosensory deficits, such as hypoacusis or serious visual impairments 2) The presence of epilepsy 3) The presence of electrolyte disorders 4) The presence of clinically and/or hemodynamically significant congenital heart defects, defined as patients with congenital heart disease who already underwent or are awaiting surgical/percutaneous correction (including palliative cardiac surgery as Glenn and/or Fontan) or who are under current treatment with cardiac medications. 5) The presence of a hypersensibility known about sulpha drugs 6) The presence of contraindications relative to the treatment by bumetanide 7) Patients already treated by diuretics 8) Any of the following abnormal laboratory values at screening: - Hemoglobin <10 g/dL - Abnormal liver function defined as any 2 or more of the following: ≥3 × upper limit of normal (ULN) aspartate aminotransferase (AST), ≥3 × ULN alanine aminotransferase (ALT), ≥3 × ULN gamma-glutamyl transpeptidase (GGT), ≥3 × ULN alkaline phosphatase (ALP), or ≥2 × ULN total bilirubin - Abnormal liver function defined as any increase of ≥5 × ULN AST or ALT - Estimated glomerular filtration rate ≤80 mL/min/1.73 m2 (calculated by the Schwartz equation) - Plasma HCO3 > 32 9) A 12-lead ECG demonstrating QTc >450 msec at Screening 10) Subject’s weight less than 25 Kg 11) Pregnancy as assessed by urine beta HCG

Where in Italy

  • Ospedale Pediatrico Bambino GesùRome, ItalyTaking people

About the trial

What the trial wants to find out

The aim of the study is to investigate the potential of 3 months of treatment with Bumetanide to rescue cognitive functions and associated psychopathological aspects in DS of Bumetanide treatment in children and adolescents with DS aged 10-16 years. The overreaching goal of our project is to test the ability of a treatment with Bumetanide to rescue cognitive functions and associated psychopathological aspects in children and adolescents with DS. As Bumetanide has been extensively used in the past in humans with little side effects, it is orally active, and it is very economical, we will test here the potentials of our therapeutic approach to be translated directly in a clinical trial on a cohort of DS patients.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A phase 2 double blind placebo controlled study on the efficacy of Bumetanide for cognitive improvement in children and adolescents with Down syndrome
Plain-language title
Bumetanide for thinking skills in children and teens with Down syndromeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
9 January 2026